Irinotel contains Irinotecan Hydrochloride, a topoisomerase I inhibitor used as a cytotoxic chemotherapy medicine for the treatment of several solid tumors.

Irinotecan is converted to its active metabolite SN-38, which inhibits topoisomerase I, an enzyme involved in DNA replication. This results in DNA damage and inhibits the proliferation of rapidly dividing cancer cells.

Irinotel is administered by intravenous infusion and is commonly used in combination chemotherapy regimens, particularly for colorectal cancer.

What is Irinotecan Hydrochloride?

Irinotecan Hydrochloride is a camptothecin-derived topoisomerase I inhibitor. By interfering with topoisomerase I-mediated DNA repair during replication, it causes DNA damage in susceptible cells.

It has an important role in chemotherapy regimens for metastatic colorectal cancer and is also used in selected treatment protocols for other malignancies.

Benefits / Uses

Irinotel (Irinotecan Hydrochloride) may be used as part of specialist chemotherapy protocols for:

• Colorectal cancer
• Metastatic colorectal cancer
• Colon cancer
• Rectal cancer
• Pancreatic cancer in selected combination regimens
• Small cell lung cancer in selected treatment settings
• Other solid tumors according to established oncology protocols

Irinotecan is frequently incorporated into combination regimens such as FOLFIRI for colorectal cancer.

Dosage Guidelines

Irinotecan dosage varies according to the cancer type, chemotherapy regimen, treatment intent, patient’s performance status, liver function, previous treatment, and other clinical factors.

• Administer by intravenous infusion under qualified oncology supervision.
• Dosage is generally calculated according to body surface area and the specific treatment protocol.
• Complete blood counts should be monitored regularly because significant neutropenia can occur.
• Patients should be monitored closely for diarrhea, which can be an important and potentially serious toxicity.
• Liver function should be assessed before and during treatment as appropriate.
• Dose modification may be required in patients experiencing significant toxicity or with impaired hepatic function.
• Appropriate management of early-onset and delayed diarrhea should be provided according to the prescribing protocol.

Wholesale & Supply

Irinotel (Irinotecan Hydrochloride Injection) may be supplied for pharmaceutical wholesale, institutional procurement, and export markets, subject to applicable regulatory requirements.

Bulk procurement enquiries may include:

• Available strengths and presentations
• Packaging configuration
• Certificate of Analysis (CoA)
• Batch documentation
• Manufacturing documentation
• Export and shipping documentation

Buying Online

Irinotecan is a prescription chemotherapy medicine and should be sourced through authorized pharmaceutical distributors, hospitals, or licensed healthcare channels.

It should be prepared, handled, and administered by qualified healthcare professionals experienced in the use of cytotoxic medicines.

Reviews

Individual responses to Irinotecan vary according to cancer type, disease stage, treatment regimen, previous therapy, and patient-specific factors. Treatment response and tolerability should be evaluated by the treating oncology team.

Quality Assurance

Irinotel (Irinotecan Hydrochloride Injection) should undergo appropriate pharmaceutical quality-control testing according to applicable standards, including relevant testing for identity, potency, purity, sterility, and other formulation-specific quality requirements.

Frequently Asked Questions

What is Irinotel used for?

Irinotel contains Irinotecan Hydrochloride and is primarily used as part of chemotherapy regimens for colorectal cancer, including metastatic colorectal cancer.

What type of medicine is Irinotecan?

Irinotecan is a camptothecin-derived cytotoxic chemotherapy medicine and topoisomerase I inhibitor.

How does Irinotecan work?

Irinotecan inhibits topoisomerase I, interfering with DNA replication and causing DNA damage that inhibits the growth of susceptible cancer cells.

How is Irinotel administered?

Irinotel is administered by intravenous infusion under the supervision of qualified healthcare professionals.

Is Irinotecan used for colorectal cancer?

Yes. Irinotecan is an important component of several chemotherapy regimens used for colorectal cancer, including combination regimens such as FOLFIRI.

What are the common side effects of Irinotecan?

Potential adverse effects include diarrhea, neutropenia, anemia, nausea, vomiting, fatigue, abdominal discomfort, and reduced appetite.

Why is diarrhea important with Irinotecan treatment?

Irinotecan can cause both early-onset and delayed diarrhea. Severe diarrhea can result in dehydration and other complications, so prompt medical management is important.

Does Irinotecan require blood-count monitoring?

Yes. Regular complete blood counts are important because Irinotecan can cause significant neutropenia and other forms of bone-marrow suppression.

Who should administer Irinotel?

Irinotel should be prescribed and administered by qualified healthcare professionals experienced in cancer chemotherapy.

Conclusion

Irinotel (Irinotecan Hydrochloride Injection) is a camptothecin-derived cytotoxic chemotherapy medicine and topoisomerase I inhibitor used particularly in treatment protocols for colorectal cancer. By interfering with DNA replication, Irinotecan damages susceptible cancer cells and inhibits their proliferation. It is frequently used in combination regimens such as FOLFIRI. Because significant neutropenia and diarrhea can occur, treatment requires specialist oncology supervision and appropriate monitoring.